While changes in 6MWD, NT-proBNP, and WHO functional class are well-established measures of PAH treatment efficacy, questionnaire-based analysis of QoL and treatment satisfaction following a switch in therapy have not been extensively investigated 18–20. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.